Leaps by Bayer led a round that also featured Amgen Ventures, Intel Capital and Alexandria Ventures Investments, taking the gene therapy technology developer's total funding to $158m.
US-based gene engineering technology developer Senti Biosciences raised $105m yesterday in a series B round led by pharmaceutical and chemicals group Bayer’s investment arm, Leaps by Bayer.
Amgen Ventures, Intel Capital and Alexandria Ventures Investments took part in the round on behalf of pharmaceutical firm Bayer, semiconductor technology producer Intel and real estate investment trust Alexandria Real Estate Equities respectively.
The round was filled out by 8VC, Gaingels, KB Investment, LifeForce Capital, Lux Capital, LifeSci Venture Partners, Matrix Partners China,…
